Deubiquitylating enzymes as cancer stem cell therapeutics

Area of Science:

• Stem cell biology
• Molecular oncology
• Epigenetics

Background:

• Core stem cell transcription factors are crucial for pluripotency and differentiation.
• Post-translational modifications, including ubiquitylation and deubiquitylation, tightly regulate stem cell and cancer stem cell (CSC) maintenance.
• CSCs share functional similarities with normal stem cells.

Purpose of the Study:

• To explore the role of deubiquitylating enzymes (DUBs) in regulating stem cell transcription factors and CSCs.
• To investigate the potential of DUBs in cellular reprogramming and carcinogenesis.
• To propose novel therapeutic strategies targeting DUBs for cancer treatment and improving induced pluripotent stem cell (iPSC) generation.

Main Methods:

• Literature review of research on stem cell transcription factors, DUBs, and cancer stem cells.
• Analysis of the regulatory mechanisms of ubiquitylation and deubiquitylation in stem cell fate.
• Exploration of the therapeutic potential of DUB inhibitors.

Main Results:

• DUBs are implicated in the regulation of core stem cell transcription factors and CSC-related proteins.
• DUBs play a significant role in cellular reprogramming and the development of cancer.
• DUBs represent promising targets for therapeutic intervention in cancer and for enhancing iPSC generation.

Conclusions:

• Understanding DUB regulatory mechanisms provides insights into stem cell pluripotency, differentiation, and carcinogenesis.
• DUBs coupled with core transcription factors may enhance protein-induced iPSC generation efficiency.
• DUB inhibitors offer a novel therapeutic approach for targeting CSCs and hold potential for revolutionizing stem cell regulation and cancer therapy.